SOPHiA GENETICS (SOPH) Common Equity (2020 - 2025)

SOPHiA GENETICS (SOPH) has 6 years of Common Equity data on file, last reported at $47.1 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 51.14% year-over-year to $47.1 million; the trailing twelve-month figure through Dec 2025 stood at $47.1 million (down 51.14% YoY), and the FY2025 full-year result was $47.1 million, down 51.14% from the prior year.
• Common Equity fell to $47.1 million in Q4 2025, from $60.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $289.7 million in Q3 2021 to a low of $47.1 million in Q4 2025.
• A 5-year average of $153.8 million and a median of $151.4 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 220.86% in 2022 and tumbled 51.14% in 2025, its largest moves.
• Tracing SOPH's Common Equity over 5 years: stood at $275.4 million in 2021, then fell by 27.33% to $200.1 million in 2022, then retreated by 24.33% to $151.4 million in 2023, then slumped by 36.29% to $96.5 million in 2024, then sank by 51.14% to $47.1 million in 2025.
• Business Quant data shows SOPH's Common Equity at $47.1 million in Q4 2025, $60.7 million in Q3 2025, and $76.7 million in Q2 2025.